Montana is advancing its plan to become a hub for experimental medical treatments, with a "right to try" law now allowing biotech companies to sell drugs that have undergone preliminary testing. Companies can pay $12,500 to have their experimental drugs reviewed by a newly established board. If approved, they can set prices and sell the treatments, potentially by year's end.

Unlike other "right to try" laws, Montana's legislation theoretically allows access to anyone who gives informed consent and can afford the treatment, extending beyond those with terminal illnesses to include individuals interested in longevity and preventive therapies. The state's Department of Health and Human Services has finalized rules requiring informed consent and review by a board comprising a doctor, scientists, and an ethicist. Supporters, like scientist Matt Kaeberlein, emphasize a rigorous process with oversight.

However, experts like Aaron Kesselheim express concerns about the potential risks of selling unproven treatments without FDA oversight. The law's unique trajectory has been driven by longevity proponents, including entrepreneur Niklas Anzinger, who sees Montana as a strong model for fast-tracking drug development. The first review board, the Montana ET RB, has been announced, with applications expected soon.